
Stifel initiates EyePoint stock with buy rating on retinal drug potential
Stifel has initiated coverage on EyePoint Inc. with a buy rating and a $40.00 price target, citing the potential of its sustained-delivery retinal disease treatment, Duravyu. The drug is expected to offer extended treatment intervals for patients with retinal diseases and its pivotal study results are anticipated in August and October. Despite recent disappointing financial results, other analysts like Guggenheim and Mizuho have maintained positive ratings due to trial progress and market positioning benefiting EyePoint.
Investing.com


























